4Wang J, Xu Z, Fang H, et al. Gene expression profiling of MPP ( + ) - treated MN9D cells: Amechanism of toxicity study [ J ]. Neurotoxicology, 2007,28:979 -987.
5Ascherio A, Chen H, Schwa.rzschild MA, et al. Caffeine postmenopausal estrogen and risk of PD [ J]. Neurology,2003,60:790.
6Benmoyal-Segal L, Soreq H. Gene-envirenment interactions in sporadic Parkinson's disease. J Neurechem,2006,97 : 1740 - 1755.
7Wang XJ', Ye M, Zhang YH, et al. CD200-CD200R regulation of mi- creglia activation in the pathogenesis of Parkinson's disease[ J]. J Neureimmunol Pharmacol, 2007, 2:259 -264.
8Tane k, Khajavi M,Thornby JI, et al. Variability and validity of Polymorphism Association Studies in Pakinsen, s disease [ J ]. Neurology( S0028 -3878) ,2000,55:533 -538.
9Warner TT, Schapira AH. Genetic and enviromental factors in the cause of parkinsen, s disease[J]. Ann Ncurol,2003, ( Suppl 3 ) : sl 6 - s23.
10Farrer MJ, Stone Jr, Lin CH, et al. Lrrk 2 G2385R is an ancestral risk factor for Parkinson "s disease in Asia [ J ]. Parkinsonism Relat Disord, 2007, 13:89 -92.
7The National Collaborating Centre for Chronic Conditions Parkinson's disease: national clinical guiddine for diagnosis and management in primary and secondary" care[M]. London: Royal college of physicians, 2006: 60-110.
